A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN). Issue 44 (19th October 2022)

• Record Type: Journal Article
• Authors: Banniettis, Natalie; Wysocki, Jacek; Szenborn, Leszek; Phongsamart, Wanatpreeya; Pitisuttithum, Punnee; Rämet, Mika; Richmond, Peter; Shi, Yaru; Dagan, Ron; Good, Lori; Papa, Melanie; Lupinacci, Robert; McFetridge, Richard; Tamms, Gretchen; Churchill, Clay; Musey, Luwy; Bickham, Kara
• Is Part Of: Vaccine. Volume 40:Issue 44(2022)
• Page Start: 6315
• Page End: 6325
• Publication Date: 2022-10-19
• Subjects: Pneumococcal conjugate vaccine -- Catch-up vaccination -- Safety -- Immunogenicity -- Pneumococcal disease; AE adverse event -- CI confidence interval -- ELISA enzyme-linked immunosorbent assay -- eVRC electronic Vaccination Report Card -- GMC geometric mean concentration -- GMFR geometric mean fold rise -- IgG immunoglobulin G -- IPD invasive pneumococcal disease -- PCV pneumococcal conjugate vaccine -- PCV10 10-valent pneumococcal conjugate vaccine -- PCV13 13-valent pneumococcal conjugate vaccine -- PCV7 7-valent pneumococcal conjugate vaccine -- PCV9 9-valent pneumococcal conjugate vaccine -- PD pneumococcal disease -- Pn ECL pneumococcal electrochemiluminescence -- PnP pneumococcal polysaccharide -- SAE serious adverse event -- V114 15-valent pneumococcal conjugate vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.09.003
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: V114 catch-up vaccination was well tolerated in children 7 months–17 years of age. V114 was immunogenic for all 15 serotypes, including those not contained in PCV13. This supports pediatric V114 catch-up vaccination, regardless of prior PCV history. Abstract: Background: Despite widespread use of pneumococcal conjugate vaccines (PCVs) in children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In addition, many children do not complete their PCV course on schedule. V114 is a 15-valent PCV that contains two epidemiologically important serotypes, 22F and 33F, in addition to the 13 serotypes present in PCV13, the licensed 13-valent PCV. Methods: This phase III descriptive study evaluated safety and immunogenicity of catch-up vaccination with V114 or PCV13 in healthy children 7 months–17 years of age who were either pneumococcal vaccine-naïve or previously immunized with lower valency PCVs (NCT03885934). Overall, 606 healthy children were randomized to receive V114 (n = 303) or PCV13 (n = 303) via age-appropriate catch-up vaccination schedules in three age cohorts (7–11 months, 12–23 months, or 2–17 years). Results: Similar proportions of children 7–11 months and 2–17 years of age reported adverse events (AEs) in the V114 and PCV13 groups. A numerically greater proportion of children 12–23 months of age reported AEs in the V114 group (79.0%) than the PCV13 group (59.4%). The proportions of children who reported serious AEs varied between different age cohorts but were generally comparable between vaccination groups. No vaccine-related serious AEs were reported, and no deaths occurred. At 30 days after the last PCV dose, serotype-specific immunoglobulin G geometric mean concentrations were comparable between vaccination groups for the 13 shared serotypes and higher in the V114 group for 22F and 33F. Conclusions: Catch-up vaccination with V114 in healthy individuals 7 months–17 years of age was generally well tolerated and immunogenic for all 15 serotypes, including those not contained in PCV13, regardless of prior pneumococcal vaccination. These results support V114 catch-up vaccination in children with incomplete or no PCV immunization per the recommended schedule.